JUNKER v. MEDICAL COMPONENTS, INC.

CourtDistrict Court, E.D. Pennsylvania
DecidedMarch 19, 2020
Docket2:13-cv-04606
StatusUnknown

This text of JUNKER v. MEDICAL COMPONENTS, INC. (JUNKER v. MEDICAL COMPONENTS, INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
JUNKER v. MEDICAL COMPONENTS, INC., (E.D. Pa. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

_______________________________________ : LARRY G. JUNKER, : CIVIL ACTION : Plaintiff, : : v. : No. 13-4606 : MEDICAL COMPONENTS, INC., et al., : : Defendants. : _______________________________________:

Goldberg, J. March 19, 2020

MEMORANDUM OPINION

Commencing on January 27, 2020, I held a bench trial on Defendants Medical Components, Inc. and Martech Medical Products, Inc.’s alleged infringement of Plaintiff Larry Junker’s patent for the handle design of what is referred to as an “introducer sheath.” The infringement verdict and my findings on Defendants’ claim of invalidity have been held under advisement pending post-trial submissions and resolution of the current discovery dispute. Permeating the trial process has been Defendants’ allegedly delinquent productions of expert reports on damages and corresponding damages theories. Plaintiff has consistently sought exclusion of these late-produced theories. I initially held this issue under advisement. As the trial record is now complete, I set forth my conclusions below regarding this discovery dispute. I. FACTUAL AND PROCEDURAL BACKGROUND Plaintiff initiated this action on August 8, 2013 for Defendants’ alleged infringement of U.S. Design Patent Number D450, 839 (the “D’839 Patent”), entitled “Handle for Introducer Sheath.” Plaintiff claims that four of Defendants’ introducer sheath products, used in the medical insertion of catheters, infringe the D’839 Patent. Defendants’ products are referred to as the Super Sheath, the Super Sheath 2.0, the Super Sheath Valved, and the Super Sheath Valved 2.0 (the “Accused Products”). Defendants assert a counterclaim for invalidity based on the allegation that Plaintiff did not invent the design claimed in the D’839 Patent. The pertinent facts regarding infringement and invalidity will be set forth in my

forthcoming Opinion on the claims and counter-claims. I recite here only those facts relevant to the expert discovery dispute before me—whether Defendants failed to comply with the requirements of Fed. R. Civ. P. 26 by belatedly disclosing a “corrected” report of its expert, Dana Trexler, and supporting documents. The Honorable L. Felipe Restrepo, who was previously assigned to this case, originally set the close of fact discovery for December 17, 2014 and the close of expert discovery for December 22, 2014. On December 22, 2014, Defendants’ damages expert, Dana Trexler, submitted her expert report (the “First Trexler Report”), calculating damages based on theories of disgorged profits and reasonable royalty.1 The next day, outside of Judge Restrepo’s deadline,

Trexler produced a “corrected” expert report (the “Second Trexler Report”), which included revised end dates of sale, earlier in time, for the Accused Products. Plaintiff moved to strike this second report as untimely and prejudicial. On May 20, 2015, Judge Restrepo denied Plaintiff’s motion and extended the close of fact and expert discovery by five months (October 16, 2015) to allow for a deposition of Trexler based on her second report. Plaintiff never sought to take this deposition. This matter was then reassigned to me on January 19, 2016.

1 Plaintiff did not pursue a reasonable royalty theory of damages at trial. (N.T., 1/27/20 (a.m.), 24:12-25:1.) On January 15, 2020, twelve days before trial was set to begin, Trexler submitted another “corrected” expert report (the “Third Trexler Report”). This report again purported to correct damages calculations by incorporating revised end dates of sale for the Accused Products. The Third Trexler Report also introduced, for the first time, “Scenario 1D”—a disgorged profits theory of damages based on Defendants’ assertion that only the handle of the accused introducer

sheaths was the relevant “article of manufacture.” On January 21, 2020, Plaintiff filed a motion seeking to preclude Trexler from testifying as to the contents of the Third Trexler Report in its entirety. I granted that motion in part, excluding those scenarios in the Third Trexler Report that calculated damages based on a theory that the filing date of this lawsuit is the appropriate date of notice to Defendants for purposes of infringement. (ECF No. 293.)2 Plaintiff’s motion to preclude Scenario 1D was held under advisement, and Trexler was permitted to testify at trial, consistent with her third report. At the close of trial, I ordered the parties to submit post-trial briefing only as to “whether Defendants, in their disclosure of the [Third Trexler Report] and its supporting documents on

January 15, 2020, failed to comply with Federal Rule of Civil Procedure 26, and whether that alleged failure resulted in prejudice to Plaintiff.” (ECF No. 283.) II. LEGAL STANDARD

Pursuant to Fed. R. Civ. P. 37(c)(1), “[i]f a party fails to provide information or identify a witness as required by Rule 26(a) or (e), the party is not allowed to use that information or witness to supply evidence on a motion, at a hearing, or at a trial, unless the failure was

2 Under this theory, Defendants were attempting to assert that Plaintiff’s disgorged profits should be calculated starting from August 8, 2013, when the lawsuit was filed, and ending with the final dates of sale for the Accused Products. This calculation was based on Defendants’ contention that 35 U.S.C. § 289, which permits recovery for disgorged profits, limits that recovery for lack of notice. I concluded that § 289 did not include this notice requirement and that 35 U.S.C. § 287, the marking provision, which does require notice, did not apply to Plaintiff. As such, I excluded any damages scenarios in the Third Trexler Report based on this theory. substantially justified or is harmless.” “Rule 37 is written in mandatory terms” because it “is designed to provide a strong inducement for disclosure of Rule 26(a) material.” Newman v. GHS Osteopathic, Inc., Parkview Hosp. Div., 60 F.3d 153, 156 (3d Cir. 1995) (internal quotation marks omitted). However, Rule 37 “expressly provides that sanctions should not be imposed if substantial justification exists for the failure to disclose, or if the failure to disclose was harmless.

Thus, the rule does not leave district courts without discretion.” Id. Courts have defined “substantial justification” as “justification to a degree that could satisfy a reasonable person that parties could differ as to whether the party was required to comply with the disclosure request. The test of substantial justification is satisfied if there exists a genuine dispute concerning compliance.” See, e.g., Sheetz v. Wal-Mart Stores, East, L.P., No. 15-2210, 2017 WL 5625768, at *2 (M.D. Pa. Nov. 22, 2017) (quoting Grider v. Keystone Health Plan Center, Inc., 580 F.3d 119 (3d Cir. 2009)). “A harmless failure involves an honest mistake, coupled with sufficient knowledge by the other party of the material that has not been produced.” Sheetz, 2017 WL 5625768, at *2 (internal quotation marks omitted). “The non-producing party

shoulders the burden of proving substantial justification for its conduct or that the failure to produce was harmless.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
JUNKER v. MEDICAL COMPONENTS, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/junker-v-medical-components-inc-paed-2020.